Skip to main content
. 2019 Dec 20;28:105034. doi: 10.1016/j.dib.2019.105034

Table 1.

In vitro hepatic metabolism data for a panel of triazole-based NAMPT inhibitors.

Compound Structure [M+H]+ Metabolic stabilitya Revealed metabolic pathwaysb
RLM HLM Pyridine
N-oxidation
Aromatic
oxidation
Aliphatic oxidation Hydrolysis Other
A1 Image 1 441 51 72
A2 Image 2 454 30 84
A3 Image 3 460 21 78
A4 Image 4 460 46 91
A5 Image 5 426 62 92
A6 Image 6 440 45 88 Oxidative
N-dealkylation
E1 Image 7 400 23 60
E2 Image 8 413 8 32
E3 Image 9 433 70 94
E4 Image 10 433 77 >99
E5 Image 11 399 31 49
E6 Image 12 413 14 61
E7 Image 13 427 16 84
C1 Image 14 442 66 (61)c 67 (87)c
C2 Image 15 476 69 (92)c 90
C3 Image 16 456 60 (89)c 86 (92)c
U1 Image 17 441 79 95
U2 Image 18 455 60 85
U3 Image 19 475 95 96
S1 Image 20 490 62 78 Oxidative
N-dealkylation
S2 Image 21 499 45 80 Oxidative
N-dealkylation
S3 Image 22 496 76 84 Oxidative
N-dealkylation
N1 Image 23 446 38 74 Oxidative
N-dealkylation
T1 Image 24 464 47 87
a

The metabolic stability was assessed by incubating each compound at 50 μM concentration with rat (RLM) or human (HLM) liver microsomes in the presence or absence of NADPH-regenerating system [4]. Residual substrate percentage was evaluated by LC-UV analysis measuring the remaining substrate after incubation.

b

For structural characterization of the metabolites, all samples were analyzed by LC-ESI-MSn.

c

Residual substrate in incubations without the presence of NADPH-regenerating system.